Schering AG receives positive CHMP opinion for EU approval of Betaferon(r)
for early use in MS patients

Berlin, May 2, 2006 - Schering AG, Germany (FSE: SCH, NYSE: SHR) announced
today that it has received a positive opinion from the Committee for
Medicinal Products for Human Use (CHMP) recommending that the European
Commission grants an extension of the indication for Betaferon(r) (interferon
beta-1b) to add the treatment of the first clinical event suggestive of
multiple sclerosis (MS) to its existing indications. A decision by the
European Commission is expected by summer 2006.

The CHMP decision is based on impressive results from the international
BENEFIT* study which showed that Betaferon(r) 250 mcg treatment in the early
phase of the disease reduced the risk of developing clinically definite MS
(CDMS) by 50 percent compared with placebo.1,2 Furthermore, patients in the
Betaferon(r) group were two times better protected3 against developing MS as
defined by the McDonald diagnostic criteria.4 The BENEFIT study is the
first study in such patients with a high-dose, high-frequency interferon
beta-1b.

"The results from the BENEFIT trial show that Betaferon consistently
reduced the risk of relapse when used in newly emerging MS, providing the
best chance of long-term efficacy to patients with multiple sclerosis and
to people who are at risk of developing MS," said Darlene Jody, MD, Head of
Schering Group's Specialized Therapeutics Global Business Unit. "The CHMP
decision represents a significant milestone, highlighting the importance of
treating patients early on - even before MS is clinically definite - to
provide rapid, early control of progression to clinically definite MS."
Betaferon(r) was first authorized in the European Union on November 30, 1995
and is currently indicated for the treatment of patients with relapsing
remitting MS and two or more relapses within the last two years, and the
treatment of patients with secondary progressive MS with active disease,
evidenced by relapses. Schering AG, Germany also submitted the BENEFIT data
to the US Food and Drug Administration (FDA) to expand the label for
Betaferon(r), marketed as Betaseron(r) in the US. An FDA decision is expected
later in 2006.

* Betaferon(r)/Betaseron(r) in Newly Emerging MS For Initial Treatment

References

1. L Kappos. Betaferon(r) in Newly Emerging Multiple Sclerosis for Initial
Treatment (BENEFIT): clinical results. Presented at ECTRIMS/ACTRIMS 2005.
2. 50 percent risk reduction based on adjustment for a standard set of
baseline covariates.
3. At the end of the study period of two years.
4. McDonald et al. Recommended Diagnostic Criteria for MS. Ann Neurol 2001;
50:121-127.

Additional information

ABOUT BENEFIT

Patients with a first clinical demyelinating event suggestive of MS and
typical MRI findings received either 250 mcg of interferon beta-1b
(Betaferon(r)) every other day or placebo as a subcutaneous injection.
Treatment continued for up to 24 months unless patients experienced a
second attack and were diagnosed with clinically definite MS. The two co-
primary efficacy outcomes were time to CDMS, based on a second clinical
demyelinating event or an Expanded Disability Status Scale (EDSS)
progression >=1.5 points, and time to MS according to the McDonald
criteria. All study participants completing the double blind study were
then invited to participate in a separate open-label follow-up study with
Betaferon(r) which will prospectively assess the impact of such early
treatment with Betaferon(r) on the long-term course of the disease for a
total observation time of five years.
BENEFIT patients included those who had a first clinical demyelinating
event either monofocal (i.e. clinical evidence of a single lesion) or
multifocal (i.e. clinical evidence of more than one lesion). Inclusion of
both patient groups is important because this is representative for a "real
life" patient population.

ABOUT BETAFERON

Betaferon(r)/Betaseron(r) was the first disease-modifying drug introduced for
MS and is a well-established treatment around the world. Betaferon(r) has the
broadest experience of any MS medication. In the US, Europe and Japan,
Betaferon(r) has been approved for all relapsing forms of MS. It is able to
reduce the number of MS episodes by one third, and the frequency of
moderate to severe episodes by as much as 50 percent. Sixteen years' follow
up of people treated with Betaferon has shown that it is safe and well
tolerated.

Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology & Andrology, Oncology,
Diagnostic Imaging as well as Specialized Therapeutics for disabling
diseases. As a global player with innovative products Schering AG aims for
leading positions in specialized markets worldwide. With in-house R&D and
supported by an excellent global network of external partners, Schering AG
is securing a promising product pipeline. Using new ideas, Schering AG aims
to make a recognized contribution to medical progress and strives to
improve the quality of life: making medicine work

This press release has been published by Corporate Communication of
Schering AG, Berlin, Germany.

Your contacts at Corporate Communication:

Media Relations: Oliver Renner, T: +49-30-468 124 31,
oliver.renner@schering.de
Media Relations: Verena von Bassewitz, T: +49-30-468 19 22 06,
verena.vonbassewitz@schering.de
Investor Relations: Peter Vogt, T: +49-30-468 128 38,
peter.vogt@schering.de
Pharma Communication: Dr Claudia Schmitt, T: +49-30-468 158 05,
claudia.schmitt@schering.de

Find additional information at: www.schering.de/eng